
<DOC>
<DOCNO>WT02-B08-81</DOCNO>
<DOCOLDNO>IA072-000460-B045-85</DOCOLDNO>
<DOCHDR>
http://www.cinp.aust.com:80/wedpres.html 203.108.64.146 19970121030732 text/html 50820
HTTP/1.0 200 OK
Date: Tue, 21 Jan 1997 02:58:50 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 50648
Last-modified: Tue, 18 Jun 1996 07:21:35 GMT
</DOCHDR>
<HTML>
<HEAD>
    <TITLE></TITLE>
</HEAD>
<BODY BGCOLOR="#ecfff1" ALINK="#ff0000">
<H5><CENTER><BR>
<BR>
<A HREF="index.htm#anchor689408"><IMG SRC="files.gif/smanlog.gif" WIDTH=
"62" HEIGHT="57" ALIGN="BOTTOM" NATURALSIZEFLAG="3"></A></CENTER>
</H5>
<H5><BR>
<BR>
XX TH C.I.N.P. CONGRESS<BR>
WORLD CONGRESS CENTRE MELBOURNE</H5>
<HR>
<H2>WEDNESDAY JUNE 26, 1996</H2>
<HR>
<H4>ROOM CODES:</H4>
LA = LA TROBE THEATRE, H2 = HOWQUA 2, H3 = HOWQUA 3, O1 = OTWAY 1, O2 =<BR>
OTWAY 2, C1 = CORRYONG 1,<BR>
C2-5 = CORRYONG 2-5, JB = JOHN BATMAN THEATRE, B1 = BELLARINE 1, B2 =<BR>
BELLARINE 2, B3 = BELLARINE 3,<BR>
B4 = BELLARINE 4, B5 = BELLARINE 5, B7 = BELLARINE 7 
<H4>PRESENTATION CODES:</H4>
BW = BREAKFAST WORKSHOP, L = PLENARY LECTURE, P = POSTER PRESENTATION,<BR>
O = ORAL/FREE COMMUNICATION, S = SYMPOSIA<BR>
<BR>
<HR><B>DAY Wednesday TIME 0730 - 0830 <BR>
<BR>
ROOM LA</B><BR>
<BR>
SESSION HEADING Breakfast Workshop<BR>
Supported by an Educational Grant from Akzo Nobel<BR>
<BR>
B-3 
<BLOCKQUOTE>Clinical Management of Schizophrenia: Practical Issues</BLOCKQUOTE>
<HR><B>DAY Wednesday TIME 0830-1100<BR>
<BR>
ROOM H2</B><BR>
<BR>
SESSION HEADING Schizophrenia: clinical<BR>
<BR>
O-16-1 Swartz, John R 
<BLOCKQUOTE>Olanzapine Use After Clozapine Induced Granulocytopenia</BLOCKQUOTE>
<BR>
O-16-2 Kishimoto, Toshifumi 
<BLOCKQUOTE>Eight-Week Administration of Antipsychotic Drugs Decreased the
Sensitivity of Vasopressin Secretion</BLOCKQUOTE>
<BR>
O-16-3 Waddington, John L 
<BLOCKQUOTE>Duration of Initially Untreated Psychosis, Negative Symptoms
and Cognitive Impairment in Schizophrenia</BLOCKQUOTE>
<BR>
O-16-4 Sachdev, Perminder 
<BLOCKQUOTE>A Case-Control Study of Neuroleptic Malignant Syndrome</BLOCKQUOTE>
<BR>
O-16-5 Sirota, Pinkhas 
<BLOCKQUOTE>Antibodies to Human Heat Shock Protein in Patients with Schizophrenia
and Major Depression</BLOCKQUOTE>
<BR>
O-16-6 Large, Matthew M 
<BLOCKQUOTE>Specific Cognitive Deficits in Schizophrenia</BLOCKQUOTE>
<BR>
O-16-7 Nakamura, Michiko 
<BLOCKQUOTE>Positive Association Between Dopamine D4 Receptor Polymorphism
and Schizophrenia</BLOCKQUOTE>
<BR>
O-16-8 Sirota, Pinkhas 
<BLOCKQUOTE>The Effect of Neuroleptic Drugs on Olfactory Sensitivity in
Schizophrenia</BLOCKQUOTE>
<BR>
O-16-9 Bersani, Giuseppe 
<BLOCKQUOTE>Haloperidol-Induced NGF Plasma Levels Changes in Schizophrenic
Patients</BLOCKQUOTE>
<BR>
O-16-10 Brewer, Warrick J 
<BLOCKQUOTE>Olfactory and Neuropsychological Deficits in High Risk and First-Episode
Psychosis</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 0830-1100<BR>
<BR>
ROOM H3 </B><BR>
<BR>
SESSION HEADING Sleep<BR>
<BR>
O-17-1 Ohayon, Maurice M 
<BLOCKQUOTE>Nightmares: Their Relationships With Mental Disorders and Sleep
Disorders</BLOCKQUOTE>
<BR>
O-17-2 Suetsugi, Masatomo 
<BLOCKQUOTE>Effects of Ethyl Loflazepate on Nocturnal Sleep and Sleep Spindle
in Normal Humans</BLOCKQUOTE>
<BR>
O-17-3 Hemmeter, Ulrich-Michael 
<BLOCKQUOTE>Relationship Between Sleep Disturbance and Pain in Patients
with Fibromyalgia and Concomitant Treatment with the 5-HT2-Receptor Antagonist
Ketanserine</BLOCKQUOTE>
<BR>
O-17-4 Chen, Char-Nie 
<BLOCKQUOTE>Delta-Hypohypnia: A New Mechanism for Chronic Intractable Insomnia?</BLOCKQUOTE>
<BR>
O-17-5 Monti, Jaime M 
<BLOCKQUOTE>Sleep and Walking in 5,7-DHT-Lesioned or (-)-Pindolol- Pretreated
Rats after Administration of Buspirone, Ipsapirone, or Gepirone</BLOCKQUOTE>
<BR>
O-17-6 Gillin, J.Christian 
<BLOCKQUOTE>Comparitive Effects of Nefazodone and Fluoxetine on Sleep in
Outpatients with Major Depresive Disorder</BLOCKQUOTE>
<BR>
O-17-7 Arriaga, Filipe 
<BLOCKQUOTE>Specificity of Sleep EEG Changes in Psychiatric Disorders: Data
From a Comparative Study</BLOCKQUOTE>
<BR>
O-17-8 Lemoine, Patrick 
<BLOCKQUOTE>Lipid Parameters in Depressed and Non-Depressed Patients With
Sleep Apneas Syndrome</BLOCKQUOTE>
<BR>
O-17-9 Hemmeter, Ulrich-Michael 
<BLOCKQUOTE>Effects of Additional Bright Light Therapy on Sleep-EEG in Depressed
Patients</BLOCKQUOTE>
<BR>
O-17-10 Sharpley, Ann L 
<BLOCKQUOTE>The Effect of Paroxetine and Nefazodone on Sleep: A Placebo
Controlled Trial</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 0830-1100<BR>
<BR>
ROOM O1</B><BR>
<BR>
SESSION HEADING Dopamine<BR>
<BR>
O-18-1 Hutson, Peter H 
<BLOCKQUOTE>Atypical Neuroleptic Profile in Rodents of L-701, 324, an Antagonist
at the Glycine/NMDA Receptor</BLOCKQUOTE>
<BR>
O-18-2 Feldon, Joram 
<BLOCKQUOTE>Clozapine in the Latent Inhibition (LI) Model: Atypical or a
Typical Neuroleptic?</BLOCKQUOTE>
<BR>
O-18-3 Vetulani, Jerzy 
<BLOCKQUOTE>Specific Activation of Limbic Dopaminergic Structures in Rat
Brain By Ca2+ Channel Blockers</BLOCKQUOTE>
<BR>
O-18-4 Crocker, Ann D 
<BLOCKQUOTE>Dopamine Antagonists Increase Muscle Tone By Blocking Dopamine
Receptors in the Substantia Nigra of the Rat</BLOCKQUOTE>
<BR>
O-18-5 Waddington, John L 
<BLOCKQUOTE>New Atypical Antipsychotics Olanzapine and ICI 204, 636 Vs Clozapine
in &quot;D1 Like&quot; Vs &quot;D2 Like&quot;<BR>
Functional Models</BLOCKQUOTE>
<BR>
O-18-6 Wong, Dona L 
<BLOCKQUOTE>Glucocorticoid-Dependen AP-2 Activation of the Phenylethanolamine-N-Methyl
Transferase Gene</BLOCKQUOTE>
<BR>
O-18-7 Creese, Ian 
<BLOCKQUOTE>Antisense &quot;Knockout&quot; of Brain Dopamine Receptors</BLOCKQUOTE>
<BR>
O-18-8 Ekman, Agneta 
<BLOCKQUOTE>Behavioural and Biochemical Effects of Dopamine D3 Antisense
Administration</BLOCKQUOTE>
<BR>
O-18-9 Hwu, Hai-Gwo 
<BLOCKQUOTE>CAG Repeat Polymorphism in Schizophrenia</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 0830-1100<BR>
<BR>
ROOM C1<BR>
</B><BR>
SESSION HEADING Depression: clinical<BR>
<BR>
O-19-1 Berk, Michael 
<BLOCKQUOTE>Acute Phase Proteins in Major Depression</BLOCKQUOTE>
<BR>
O-19-2 Mauri, Massimo Carlo 
<BLOCKQUOTE>Plasma and Plaelet Amino Acids in Major Depressed Patients Treated
With Fluvoxamine</BLOCKQUOTE>
<BR>
O-19-3 Gupta, Ramesh K 
<BLOCKQUOTE>Refractory Depression a Biochemical Hypothesis</BLOCKQUOTE>
<BR>
O-19-4 Fahlen, Tom 
<BLOCKQUOTE>Buspiron Augmentation of SSRI Therapy in Treatment-Refractory
Depression</BLOCKQUOTE>
<BR>
O-19-5 Szegedi, Armin 
<BLOCKQUOTE>Pramipexole in Major Depression - An Open Clinical Trial</BLOCKQUOTE>
<BR>
O-19-6 Bisserbe, Jean-Claude 
<BLOCKQUOTE>A Six Month Sertraline Fluoxetine Comparitive Study in Depressed
Outpatients: Outcome and Cost</BLOCKQUOTE>
<BR>
O-19-7 Timotijevic, Ivana 
<BLOCKQUOTE>Comparison of Efficacy and Tolerability of Fluoxetine in Ambulatory
and Hospitalized Patients with Major Depression</BLOCKQUOTE>
<BR>
O-19-8 Starmer, Graham 
<BLOCKQUOTE>Comparison of Effects of Paroxetine and Amitriptyline on Driving
and Psychomotor Performance in Depression</BLOCKQUOTE>
<BR>
O-19-9 Ciprian-Ollivier, Jorge 
<BLOCKQUOTE>SSRI, L-Tryptophan and Serotonin Syndrome. Experience with 75
Patients</BLOCKQUOTE>
<BR>
O-19-10 Joubert, Andre F 
<BLOCKQUOTE>Antidepressants and Weight: A Comparitive Study of Four Antidepressants</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM H2</B><BR>
<BR>
SESSION HEADING Alzheimer's disease and dementia<BR>
<BR>
O-20-1 Morokawa, Yumiyo 
<BLOCKQUOTE>Similarities in Cognitive Impairment Profiles Between Mild Dementia
of Alzheimer Type and Anticholinergic Agent</BLOCKQUOTE>
<BR>
O-20-2 Schweitzer, Isaac 
<BLOCKQUOTE>Use of Anticholinergic Eye Drops in Differentiating Alzheimer's
Disease and Depression</BLOCKQUOTE>
<BR>
O-20-3 Riedel, Wim J 
<BLOCKQUOTE>Scopolamine is a Model of Memory Dysfunction, not of Ageing</BLOCKQUOTE>
<BR>
O-20-4 Bodick, Neil C 
<BLOCKQUOTE>The M1 Muscarinic Agonist Xanomeline Improves Both Cognitive
and Behavioural Deficits in Alzheimer's Disease</BLOCKQUOTE>
<BR>
O-20-5 Dhawan, Bhola N 
<BLOCKQUOTE>Pharmacological Studies on Bacopa Monniera, An Ayurvedic Nootropic
Agent</BLOCKQUOTE>
<BR>
O-20-6 Mander, Alastair G 
<BLOCKQUOTE>The Effects of Rilmenidine on Memory, Attention and Planning
in the Elderly</BLOCKQUOTE>
<BR>
O-20-7 Fagarasan, Mirela O 
<BLOCKQUOTE>The Mechanism of Amyloid B-Peptide (1-42) Toxicity in PC12 Cells</BLOCKQUOTE>
<BR>
O-20-8 Altstiel, Larry D 
<BLOCKQUOTE>Prospective Study of the Effect of APOE Genotype on Cognitive
Performance In the Very Old</BLOCKQUOTE>
<BR>
O-20-9 Kishitani, Kazuyuki K 
<BLOCKQUOTE>Cognitive Process Produces Inactivated Serotonin</BLOCKQUOTE>
<BR>
O-20-10 Hogervorst, Eef 
<BLOCKQUOTE>Hypoxia and Hyperventilation as Models for Cognitive Deficiencies</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM H3</B><BR>
<BR>
SESSION HEADING Receptors and second messengers<BR>
<BR>
O-21-1 Lopez-Ibor, Juan F 
<BLOCKQUOTE>Localization of 5-HT1a, MR and GR mRNA in Human Hippocampus</BLOCKQUOTE>
<BR>
O-21-2 Popoli, Maurizio 
<BLOCKQUOTE>Long-Term Changes Induced By Antidepressant Drugs in the Presynaptic
Release Machinery</BLOCKQUOTE>
<BR>
O-21-3 Fillion, Gilles NB 
<BLOCKQUOTE>Modulation of 5-HT Activity by a New Endogenous Peptide 5HT
Moduline Directly Interacting at 5HT1B/1D Receptors</BLOCKQUOTE>
<BR>
O-21-4 Newman, Michael E 
<BLOCKQUOTE>Effects of Psychoactive Agents on Second Messenger Formation
in Rat Brain as Determined by In Vivo Micro-Dialysis</BLOCKQUOTE>
<BR>
O-21-5 Pandey, Ghanshyam N 
<BLOCKQUOTE>Regulation of 5HT2A Receptors and Protein Kinase C By Dexamethasone
and Corticosterone in the Rat Brain</BLOCKQUOTE>
<BR>
O-21-6 Borsodi, Anna 
<BLOCKQUOTE>Opioid Receptor Binding Properties of [3H] Buprenorphine in
Rat Brain</BLOCKQUOTE>
<BR>
O-21-7 Popoli, Maurizio 
<BLOCKQUOTE>Characterization of Synaptotagmini Phosphorylation By Ca2+/Calmodulin-Ca2+/Phospholipid
Binding</BLOCKQUOTE>
<BR>
O-21-8 Sapronov, Nikolai S 
<BLOCKQUOTE>The Study of Signal Transduction During the Action of Some Memory
Modulators</BLOCKQUOTE>
<BR>
O-21-9 Marazziti, Donatella 
<BLOCKQUOTE>Protein Kinase C Regulates Platelet Serotonin Transporter</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM C1</B><BR>
<BR>
SESSION HEADING Antipsychotics<BR>
<BR>
O-22-1 Lee, Min-Soo 
<BLOCKQUOTE>Co-administration of Paroxetine and Haloperidol in Chronic Schizophrenia</BLOCKQUOTE>
<BR>
O-22-2 Silver, Henry 
<BLOCKQUOTE>SSRI Augmentation of Antipsychotics in the Treatment of Negative
Symptoms</BLOCKQUOTE>
<BR>
O-22-3 Burgoyne, Karl S 
<BLOCKQUOTE>Olanzapine X Haloperidol: The Results of a Double Blind Study
On Acute Psychotic Patients</BLOCKQUOTE>
<BR>
O-22-4 Arvanitis, Lisa A 
<BLOCKQUOTE>'Seroquel' (ICI 204, 636): An Atypical Antipsychotic: Results
From a Multiple Fixed Dose,<BR>
Placebo-Controlled Study</BLOCKQUOTE>
<BR>
O-22-5 Fritze, Jurgen 
<BLOCKQUOTE>Tolerability of Low Dose Neuroleptics: A Pseudoprospective,
Blind Investigation of Flupenthixol</BLOCKQUOTE>
<BR>
O-22-6 Battegay, Raymond 
<BLOCKQUOTE>Retrospective Study on Longtime Treatment with Clozapine</BLOCKQUOTE>
<BR>
O-22-7 Cooper, Stephen J 
<BLOCKQUOTE>Zotepine in Acute Exacerbation of Schizophrenia: A Comparison
Versus Chlorpromazine and Placebo</BLOCKQUOTE>
<BR>
O-22-8 Svestka, Jaromir A 
<BLOCKQUOTE>Controlled Comparison of Terguride and Perphenazine in Acute
Schizophrenia</BLOCKQUOTE>
<BR>
O-22-9 Bastaman, Tun K 
<BLOCKQUOTE>A Clinical Trial with Risperidon on Chronic Schizophrenics</BLOCKQUOTE>
<BR>
O-22-10 Steiger, Axel 
<BLOCKQUOTE>Clinical Trial on Antipsychotic Effects of the Sigma Ligand
Panamesine in Schizophrenia</BLOCKQUOTE>
<BR>
O-22-11 D'Souza, Cyril D 
<BLOCKQUOTE>Dose Response of D-Cycloserine, a Partial NMDA-Glycine Site
Agonist, in Schizophrenia</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 0830-1100<BR>
<BR>
ROOM LA</B><BR>
<BR>
SESSION HEADING Social phobia: a debilitating disease with a new treatment
option<BR>
Sponsored by F.Hoffman LaRoche<BR>
Chair: B James (Australia) Co-chair: M Stein (USA)<BR>
<BR>
S-38-1 Montgomery, Stuart A 
<BLOCKQUOTE>Treatment of Social Phobia</BLOCKQUOTE>
<BR>
S-38-2 Lopez-Ibor, Juan 
<BLOCKQUOTE>Social Phobia: A Debilitating Disease That Needs Treatement</BLOCKQUOTE>
<BR>
S-38-3 LeCrubier, Yves 
<BLOCKQUOTE>Comorbidities in Social Phobia</BLOCKQUOTE>
<BR>
S-38-4 Stein, Murray B 
<BLOCKQUOTE>Social Phobia: What is it and Who Has it?</BLOCKQUOTE>
<BR>
S-38-5 Tiller, John<BR>
<BR>
<HR><B>DAY Wednesday TIME 0830-1100<BR>
<BR>
ROOM O2<BR>
</B><BR>
SESSION HEADING Stress, hypersecretion of corticosteroids, monoaminergic
disturbance: a trias operational in the occurance of depression?<BR>
Chair: H Van Praag (The Netherlands) Co-chair: D Nicholson (The Netherlands)<BR>
<BR>
S-39-1 de Kloet, Ronald E 
<BLOCKQUOTE>Corticosteroid-serotonin Interaction in Rat Brain: Pathophysiological
Implications</BLOCKQUOTE>
<BR>
S-39-2 van Praag, Herman M 
<BLOCKQUOTE>Stress; Corticosteroids Hypersecretion; A Mono-Aminergic Dysregulation.
A Depressogenic Cascade?</BLOCKQUOTE>
<BR>
S-39-3 Post, Robert M 
<BLOCKQUOTE>Long-term Impact of Stressors and Affective Episodes on Vulnerability
to Recurrence and Cycling</BLOCKQUOTE>
<BR>
S-39-4 Nicholson, David C 
<BLOCKQUOTE>Disturbed Hypothalamic-pituitary Axis in Depression</BLOCKQUOTE>
<BR>
S-39-5 Holsboer, Florian 
<BLOCKQUOTE>Antidepressants and the HPA System</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 0830-1100<BR>
<BR>
ROOM B1</B><BR>
<BR>
SESSION HEADING AMPA receptor desensitization and cognition enhancing drugs<BR>
Chair: A Guidotti (USA)<BR>
<BR>
S-40-1 Lodge, David 
<BLOCKQUOTE>Interactions Between Cyclothiazide and 2,3-Benzodiazepines In
Vivo and In Vitro</BLOCKQUOTE>
<BR>
S-40-2 Partin, Kathy 
<BLOCKQUOTE>Allosteric Modulation of AMPA Receptor Function</BLOCKQUOTE>
<BR>
S-40-3 Rothman, Steven M 
<BLOCKQUOTE>Thiazide Derivatives Block Rapid AMPA Receptor Desensitization</BLOCKQUOTE>
<BR>
S-40-4 Costa, Erminio 
<BLOCKQUOTE>Positive Allosteric Modulation of AMPA or GABAa Receptors Antagonizes
Alprazolam Induced Learning Impairment in Monkeys</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 0830-1100<BR>
<BR>
ROOM B5</B><BR>
<BR>
SESSION HEADING Dopamine and depressive illness<BR>
Chair: G Goodwin (UK) Co-chair: G Parker (Australia)<BR>
<BR>
S-41-1 Fibiger, Hans C 
<BLOCKQUOTE>Dopamine and Reward Mechanisms: Implications for Mood Disorders</BLOCKQUOTE>
<BR>
S-41-2 Robbins, Trevor W 
<BLOCKQUOTE>Functions of the Central Dopamine Systems in Cognition: Relevance
to Human Depression</BLOCKQUOTE>
<BR>
S-41-3 Parker, Gordon 
<BLOCKQUOTE>Retardation and the Classification of Major Depression</BLOCKQUOTE>
<BR>
S-41-4 Goodwin, Guy M 
<BLOCKQUOTE>Investigation of Dopamine Receptor Function in Major Depression</BLOCKQUOTE>
<BR>
S-41-5 Ebert, Dieter 
<BLOCKQUOTE>Sleep Deprivation, Mood Enhancement and Dopamine Receptor Binding
in Vivo in Depression</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1600-1730<BR>
<BR>
ROOM B2</B><BR>
<BR>
SESSION HEADING Placebo effects in multi-center trials<BR>
Chair: W Fleischhacker (Austria) Co-chair: J M Kane (USA)<BR>
<BR>
S-42-1 Kane, John M 
<BLOCKQUOTE>Placebo Response in Schizophrenia</BLOCKQUOTE>
<BR>
S-42-2 Quitkin, Frederic M 
<BLOCKQUOTE>Pattern Analysis Predicts Relapse On Fluoxetine and Placebo
During Continuation</BLOCKQUOTE>
<BR>
S-42-3 Rickels, Karl 
<BLOCKQUOTE>Are Drug-Placebo Differences in the Treatment of Anxiety Disorders
Shrinking over the Years?</BLOCKQUOTE>
<BR>
S-42-4 Uhlenhuth, Eberhard H 
<BLOCKQUOTE>Growing Placebo Effect -- The Problem in Recent Therapeutic
Trials?</BLOCKQUOTE>
<BR>
S-42-5 Geerlings, Peter J 
<BLOCKQUOTE>Placebo Effects in Alcohol Dependence</BLOCKQUOTE>
<BR>
<BR>
S-42-6 Fleischhacker, Wolfgang W 
<BLOCKQUOTE>Placebo-Induced Side Effects in Clinical Trials with Schizophrenic
Patients</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 0830-1100<BR>
<BR>
ROOM B3</B><BR>
<BR>
SESSION HEADING Neurobiological basis of relapse prediction in stimulant-
induced psychosis and schizophrenia<BR>
Chair: K Yui (Japan) Co-chair: S Ali (USA)<BR>
<BR>
S-43-1 Yui, Kunio 
<BLOCKQUOTE>Noradrenergic Hyperactivity and Spontaneous Recurrence Methamphetamine
Psychosis</BLOCKQUOTE>
<BR>
S-43-2 Ali, Syed F 
<BLOCKQUOTE>Schizophrenia: Correlation With Phencyclidine-Induced Psychosis
and Neurochemical Mechanisms</BLOCKQUOTE>
<BR>
S-43-3 Kuczenski, Ronald 
<BLOCKQUOTE>Behavioral and Neurotransmitter Responses to a &quot;Binge&quot;
Pattern of Amphetamine Administration</BLOCKQUOTE>
<BR>
S-43-4 Lieberman, Jeffrey A 
<BLOCKQUOTE>Evidence for Sensitization in the Early Stage of Schizophrenia</BLOCKQUOTE>
<BR>
S-43-5 van Kammen, Daniel P 
<BLOCKQUOTE>Predicting Duration of Clinical Stability Following Haloperidol
Withdrawal in Schizophrenia</BLOCKQUOTE>
<BR>
S-43-6 Angrist, Burt 
<BLOCKQUOTE>Cocaine Psychosis and Addiction: A Role for Sensitization and
Search for Substrates</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 0830-1100<BR>
<BR>
ROOM B4</B><BR>
<BR>
SESSION HEADING Intracellular Targets for the Action of Antidepressants<BR>
Chair: G Racagni (Italy) Co-chair: S Yamawaki (Japan)<BR>
<BR>
S-44-1 Avissar, Sofia 
<BLOCKQUOTE>Receptor-Coupled G Protein Function in Mood Disorders</BLOCKQUOTE>
<BR>
S-44-2 Kagaya, Ariyuki 
<BLOCKQUOTE>Intracellular Calcium Signalling-Related System in Affective
Disorders and their Treatment</BLOCKQUOTE>
<BR>
S-44-3 Racagni, Giorgio 
<BLOCKQUOTE>Protein Phosphorylation as Intracellular Target of Antidepressants</BLOCKQUOTE>
<BR>
S-44-4 Asakura, Mikio 
<BLOCKQUOTE>Protein Phosphorylation Involved in the Mechanism of Antidepressant
Drugs</BLOCKQUOTE>
<BR>
S-44-5 Lesch, Klaus-Peter 
<BLOCKQUOTE>Antidepressant Drug-Induced Modulation of Serotonergic Gene
Expression</BLOCKQUOTE>
<BR>
S-44-6 Yamawaki, Shigeto 
<BLOCKQUOTE>Intracellular Signalling System as a New Direction in Affective
isorders Research</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 0830-1100<BR>
<BR>
ROOM JB</B><BR>
<BR>
SESSION HEADING Chemical Neuroanatomy of the Human Brain, Post Mortem Strategies<BR>
Chair: G Sedvall (Sweden) Co-chair: F Mendelsohn (Australia)<BR>
<BR>
S-45-1 Sedvall, Goran C 
<BLOCKQUOTE>Chemical Neuroanatomy of the Human Brain, Post-Mortem Strategies</BLOCKQUOTE>
<BR>
S-45-2 Hall, Hakan 
<BLOCKQUOTE>Distribution of Dopamine Receptor Subtypes in the Post-Mortem
Human Brain</BLOCKQUOTE>
<BR>
S-45-3 Palacios, J M 
<BLOCKQUOTE>Mapping and Characterizing 5HT Receptors in the Human Brain</BLOCKQUOTE>
<BR>
S-45-4 Young, 
<BLOCKQUOTE>Excitatory Amino Acids in the Human Brain</BLOCKQUOTE>
<BR>
S-45-5 Hurd, Yasmin 
<BLOCKQUOTE>Imaging the Gene Expression of Opioid Peptides in the Post-Mortem
Human Brain</BLOCKQUOTE>
<BR>
S-45-6 Quirion, Remi 
<BLOCKQUOTE>Cholinergic and Peptidergic Markers in the Alzheimer's Brain:
Possible Relevance to Therapy</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 0830-1100<BR>
<BR>
ROOM B7</B><BR>
<BR>
SESSION HEADING Potential role of sigma receptors in psychiatric disorders:
from receptors to clinical investigation<BR>
Chair: G Debonnel (Canada) Co-chair: B Leonard (Ireland)<BR>
<BR>
S-46-1 Brent, Paul J 
<BLOCKQUOTE>Sigma Receptor Ligands Modulate Protein Phosphorylation and
Intracellular Free Calcium Levels in Rat Forebrain Synaptosomes</BLOCKQUOTE>
<BR>
S-46-2 Debonnel, Guy 
<BLOCKQUOTE>Modulation of the NMDA Response By Sigma1, Sigma2 Ligands and
Neurosteroids: Evidence for the Existance of Several Sigma Receptors</BLOCKQUOTE>
<BR>
S-46-3 Leonard, Brian E 
<BLOCKQUOTE>Putative Endogenous Ligands for Sigma Receptors</BLOCKQUOTE>
<BR>
S-46-4 Nabeshima, Toshitaka 
<BLOCKQUOTE>Interactions Between NMDA/Nitric Oxide Systems and Receptors
in Learning and Memory in Mice</BLOCKQUOTE>
<BR>
S-46-5 Walker, Michael J 
<BLOCKQUOTE>Role of Sigma Receptors in Motor Control</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM LA</B><BR>
<BR>
SESSION HEADING Chronic treatment of anxiety: benzodiazepines and beyond<BR>
Chair: K Rickels (USA) Co-chair: J C Bisserbe (France)<BR>
<BR>
S-47-1 Boyer, Patrice 
<BLOCKQUOTE>Chronic Benzodiazepine Use in the General Population</BLOCKQUOTE>
<BR>
S-47-2 Bisserbe, Jean-Claude 
<BLOCKQUOTE>Benzodiazepines Use in the Medically Ill Population: Impact
of Psychopathology and Somatic Morbidity</BLOCKQUOTE>
<BR>
S-47-3 Potokar, John P 
<BLOCKQUOTE>Receptor Mechanisms of Benzodiazepine Dependence</BLOCKQUOTE>
<BR>
S-47-4 Schweizer, Edward 
<BLOCKQUOTE>The Pharmacological Management of Benzodiazepine Withdrawal</BLOCKQUOTE>
<BR>
S-47-5 Rickels, Karl 
<BLOCKQUOTE>Benzodiazepines and Antidepressants in the Treatment of Generalized
Anxiety</BLOCKQUOTE>
<BR>
S-47-6 Stahl, Stephen M 
<BLOCKQUOTE>Serotonergic Agents in the Treatment of Anxiety: Is the 5HT1A
Receptor a Good Target?</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM O1</B><BR>
<BR>
SESSION HEADING Behavioural sensitization as a model of functional psychoses<BR>
Chair: T Koyama (Japan) Co-chair: P Kalivas (USA)<BR>
<BR>
S-48-1 Ohmori, Tetsuro 
<BLOCKQUOTE>The Role of Environment and Cognitive Function in the Development
of Behavioural Sensitization</BLOCKQUOTE>
<BR>
S-48-2 Kalivas, Peter W 
<BLOCKQUOTE>Sensitization to Psychostimulants Depends Upon Glutamate Transmission
in the Nucleus Accumbens</BLOCKQUOTE>
<BR>
S-48-3 Fibiger, Hans C 
<BLOCKQUOTE>On the Functional Significance of Behavioural Sensitization</BLOCKQUOTE>
<BR>
S-48-4 Cunningham, Kathryn A 
<BLOCKQUOTE>The Integrity of Serotonin Function and Sensitization to Cocaine</BLOCKQUOTE>
<BR>
S-48-5 Kajii, Yasushi 
<BLOCKQUOTE>Stimulant-Induced Behavioural Sensitization and Gene Expression
in Developing Rats</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM O2</B><BR>
<BR>
SESSION HEADING Genetic prediction of medication responses with patients
with major psychiatric disorders Chair: E Smeraldi (Italy) Co-chair: B Lerer
(Israel)<BR>
<BR>
S-49-1 Macciardi, Fabio 
<BLOCKQUOTE>Genetic Mechanisms in Response to Haloperidol and Risperidone
Treatments</BLOCKQUOTE>
<BR>
S-49-2 Kennedy, James L 
<BLOCKQUOTE>Genetic Studies of Dopamine and Serotonin System Genes in Clinical
Response to Clozapine</BLOCKQUOTE>
<BR>
S-49-3 Nothen, Marlens M 
<BLOCKQUOTE>Molecular Genetic Studies of Variation in Dopamine and Serotonin
Receptor Genes</BLOCKQUOTE>
<BR>
S-49-4 Souery, Daniel 
<BLOCKQUOTE>Genetic Markers and Lithium Prophylactic Treatment of Bipolar
Affective Disorder</BLOCKQUOTE>
<BR>
S-49-5 Lerer, Bernard 
<BLOCKQUOTE>Pharmogenetic Factors in Schizophrenia: Treatment Response and
Adverse Effects</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM B1<BR>
</B><BR>
SESSION HEADING Uses of narcotic antagonists in the treatment of addiction<BR>
Chair: H Kleber (USA) Co-chair: J van Ree (The Netherlands)<BR>
<BR>
S-50-1 Kleber, Herbert D 
<BLOCKQUOTE>Ultra-Rapid Opioid Detoxification Using Narcotic Antagonists</BLOCKQUOTE>
<BR>
S-50-2 Woods, James H 
<BLOCKQUOTE>Naltrexone: Critical Review of Studies in Animals For Their
Relevance to Alcoholism Treatment</BLOCKQUOTE>
<BR>
S-50-3 O'Brien, Charles P 
<BLOCKQUOTE>Narcotic Antagonists in the Treatment of Alcoholism</BLOCKQUOTE>
<BR>
S-50-4 Fischman, Marian W 
<BLOCKQUOTE>Use of Narcotic Antagonist in Treating Opioid Addiction</BLOCKQUOTE>
<BR>
S-50-5 Tempesta, Enrico 
<BLOCKQUOTE>European Experience With Narcotic Antagonists in the Treatment
of Opioids and Alcohol Dependence</BLOCKQUOTE>
<BR>
S-50-6 Van Ree, Jan M 
<BLOCKQUOTE>Endogenous Epioids and Experimental Addiction</BLOCKQUOTE>
<BR>
S-50-7 Kleber, Herbert D 
<BLOCKQUOTE>Uses of Narcotic Antagonists in the Treatment of Addiction</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM C2</B><BR>
<BR>
SESSION HEADING MAO isoforms as targets for psychotropic and neuroprotective
drugs<BR>
Chair: B Scatton (France) Co-chair: M Youdim (Israel)<BR>
<BR>
S-51-1 Finberg, John PM 
<BLOCKQUOTE>Modulation of Cerebral Monoamine Release by MAO Inhibitors</BLOCKQUOTE>
<BR>
S-51-2 Youdim, Moussa BH 
<BLOCKQUOTE>Potentials of MAO-A and B Inhibitors in the Clinic</BLOCKQUOTE>
<BR>
S-51-3 Amrein, Roman MK 
<BLOCKQUOTE>The Rima Moclobemide: More Than an Effective Antidepressant?</BLOCKQUOTE>
<BR>
S-51-4 Curet, Olivier 
<BLOCKQUOTE>Pharmacological Profile of Befloxatone, A Reversible and Selective
MAO-A Inhibitor</BLOCKQUOTE>
<BR>
S-51-5 Rosenzweig, Pierre 
<BLOCKQUOTE>Clinical Pharmacology Profile of Befloxatone</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM JB</B><BR>
<BR>
SESSION HEADING Neuroimaging in psychiatry - Part 2<BR>
Chair: F Mendelsohn (Australia) Co-chair: G Sedvall (Sweden)<BR>
<BR>
S-52-1 Farde, Lars 
<BLOCKQUOTE>PET-Studies on the Dopamine System In-Vivo</BLOCKQUOTE>
<BR>
S-52-2 Suhara, Tetsuya 
<BLOCKQUOTE>Imaging of the Brain Serotonin System</BLOCKQUOTE>
<BR>
S-52-3 Andreasen, Nancy C 
<BLOCKQUOTE>Mapping the Future in Schizophrenia</BLOCKQUOTE>
<BR>
S-52-4 O'Sullivan, Brendan T 
<BLOCKQUOTE>Applications of H2 15O PET Activation Studies in Normal and
Disordered Brain Function</BLOCKQUOTE>
<BR>
S-52-5 Silberstein, Richard B 
<BLOCKQUOTE>High Temporal Resolution Functional Brain Electrical Activity
Mapping in Psychiatry</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM B2</B><BR>
<BR>
SESSION HEADING Quality of life issues in medicated psychiatric patients
- implications for clinical practice and health economics<BR>
Chair: G Awad (Canada) Co-chair: M Schmitz (Austria)<BR>
<BR>
S-53-1 Katschnig, Heinz 
<BLOCKQUOTE>Quality of Life in Depression - How Should It Be Measured?</BLOCKQUOTE>
<BR>
S-53-2 Herrman, Helen E 
<BLOCKQUOTE>Development of the Who Quality of Life Assessment Instrument
(WHOQOL) and Its Application in Assessing the Recovery from Depression</BLOCKQUOTE>
<BR>
S-53-3 Awad, George A 
<BLOCKQUOTE>Basic Issues in Quality of Life (QL) Assessment in Psychiatry-
The Leap From QL to Health Economics</BLOCKQUOTE>
<BR>
S-53-4 Schmitz, Margot 
<BLOCKQUOTE>Quality of Life and Quality of Care in Severley Psychotic Patients</BLOCKQUOTE>
<BR>
S-53-5 Stedman, Terry J 
<BLOCKQUOTE>Are Single Figure Generic Quality of Life Measures Sensitive
to Change With Mental Health Interventions?</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM B3</B><BR>
<BR>
SESSION HEADING The neuronal basis of attentional state: recent advances
in locus coeruleus<BR>
Chair: M Christie (Australia) Co-chair: G Aston-Jones (USA)<BR>
<BR>
S-54-1 Aston-Jones, Gary 
<BLOCKQUOTE>Activity of Noradrenergic Locus Coeruleus (LC) Neurona in Monkey
During Performance of an Attentional Task</BLOCKQUOTE>
<BR>
S-54-2 Williams, John T 
<BLOCKQUOTE>The Integration of Intrinsic Properties and Synaptic Inputs
in Locus Coeruleus</BLOCKQUOTE>
<BR>
S-54-3 Christie, MacDonald J 
<BLOCKQUOTE>Electrical and Dye Coupling in Locus Coeruleus Neurones During
Postnatal Development</BLOCKQUOTE>
<BR>
S-54-4 Osborne, Peregrine B 
<BLOCKQUOTE>Neurotransmitter Modulation of Coupling in Locus Coeruleus</BLOCKQUOTE>
<BR>
S-54-5 Robbins, Trevor W 
<BLOCKQUOTE>Experimental Studies of the Functions of Central Noradrenaline
in Animals and Humans</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM B4</B><BR>
<BR>
SESSION HEADING Genetics and alcoholism<BR>
Chair: K Merikangas (USA)<BR>
<BR>
S-55-1 Merikangas, Kathleen R 
<BLOCKQUOTE>Familial Transmission of Alcoholism and Anxiety Disorders</BLOCKQUOTE>
<BR>
S-55-2 Heath, Andrew C 
<BLOCKQUOTE>Gender Differences in the Genetic Contribution to Alcoholism
Risk: Findings From the Australian Twin Panel</BLOCKQUOTE>
<BR>
S-55-3 Maier, Wolfgang 
<BLOCKQUOTE>Association Between Alcoholism and Genetic Markers</BLOCKQUOTE>
<BR>
S-55-4 Martin, Nick G 
<BLOCKQUOTE>Effects of Alcohol Dehydrogenase Genotype on Alcohol Pharmacokinetics:
A Model System For QTL Analysis</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1330-1600<BR>
<BR>
ROOM B5</B><BR>
<BR>
SESSION HEADING A neurodevelopmental basis to schizophrenia: challenges
and limitations<BR>
Chair: J Waddington (Ireland) Co-chair: R Quirion (Canada)<BR>
<BR>
S-56-1 Weinberger, Daniel R 
<BLOCKQUOTE>The Neurodevelopmental Hypothesis of Schizophrenia: A Critical
Clinical Perspective</BLOCKQUOTE>
<BR>
S-56-2 Wyatt, Richard J 
<BLOCKQUOTE>Schizophrenia: A Neurodevelopmental and Progressive Disorder</BLOCKQUOTE>
<BR>
S-56-3 Waddington, John L 
<BLOCKQUOTE>Neurodevelopmental Disturbance in Schizophrenia As the Origin
of Later, Active Disease?</BLOCKQUOTE>
<BR>
S-56-4 Srivastava, Lalit K 
<BLOCKQUOTE>Neural Cell Adhesion Molecules and the Developmental Hypothesis
of Schizophrenia</BLOCKQUOTE>
<BR>
S-56-5 Vita, Antonio 
<BLOCKQUOTE>Neuroimaging in Schizophrenia: From Active to Chronic Illness</BLOCKQUOTE>
<BR>
<HR><B>DAY Wednesday TIME 1600-1730<BR>
<BR>
ROOM C3-5</B><BR>
<BR>
SESSION HEADING Poster Presentations<BR>
<BR>
P-15-1 Brecher, Martin B 
<BLOCKQUOTE>Long-Term Safety of Risperidone</BLOCKQUOTE>
<BR>
P-15-2 Jalenques, Isabelle 
<BLOCKQUOTE>Weight Gain and Long Term Clozapine Efficiency</BLOCKQUOTE>
<BR>
P-15-3 Kazamatsuri, Hajime 
<BLOCKQUOTE>Megacolon Associated with Longterm Neuroleptic Medication</BLOCKQUOTE>
<BR>
P-15-4 Brunner, Elizabeth R 
<BLOCKQUOTE>Relationship Between Akathisia and Parkinsonism in Schizophrenic
Patients who Receive Neuroleptics</BLOCKQUOTE>
<BR>
P-15-5 Street, Jamie S 
<BLOCKQUOTE>Comparison of Extrapyramidal Syndromes Between Olanzapine and
Placebo in Schizophrenia</BLOCKQUOTE>
<BR>
P-15-6 Hong, Walter W 
<BLOCKQUOTE>'Seroquel' (ICI 204, 636) Does Not Differ From Placebo in the
Incidence of EPS or Effect on Plasma Prolactin</BLOCKQUOTE>
<BR>
P-15-7 Nishikawa, Tadashi 
<BLOCKQUOTE>Respiratory Dyskinesia: A Prevalence Study Using Computer Analysis
of Spirograph Data</BLOCKQUOTE>
<BR>
P-15-8 Atkin, Karen J 
<BLOCKQUOTE>The Incidence of Neutropenia and Agranulocytosis in Patients
Treated with Clozapine in the UK and Ireland</BLOCKQUOTE>
<BR>
P-15-9 Seifertova, Dagmar 
<BLOCKQUOTE>Treatment of the Neuroleptic Malignant Syndrome</BLOCKQUOTE>
<BR>
P-15-10 Moroni, Anna M 
<BLOCKQUOTE>Considerations about Neuroleptics' Use: Past, Present and Future</BLOCKQUOTE>
<BR>
P-15-11 Peet, Malcolm 
<BLOCKQUOTE>Teaching Schizophrenic Patients about their Neuroleptic Medication</BLOCKQUOTE>
<BR>
P-15-12 Paunovic, Vladimir R 
<BLOCKQUOTE>Effects of Clozapine on Cognitive Performance in Schizophrenia.
A Clinical Study</BLOCKQUOTE>
<BR>
P-15-13 Timotijevic, Ivana 
<BLOCKQUOTE>Genetic-Epidemiology of Schizophrenia: A Pilot Study</BLOCKQUOTE>
<BR>
P-15-14 Ohara, Koichi 
<BLOCKQUOTE>Intact 5-HT2A Receptor Gene in Schizophrenia</BLOCKQUOTE>
<BR>
P-15-15 Ripova, Daniela B 
<BLOCKQUOTE>Inositol-Lipid Signalling System in Blood Platelets of Schizophrenic
Patients</BLOCKQUOTE>
<BR>
P-15-16 Liu, Wen-Chien 
<BLOCKQUOTE>Changes of Platelet Serotonin-2 Receptors in Chronic Neuroleptic-Treated
Schizophrenia</BLOCKQUOTE>
<BR>
P-15-17 Lahti, Robert A 
<BLOCKQUOTE>Dopamine D2-Family Receptors in Human Postmortem Brain: Comparison
of Normals and Schizophrenics</BLOCKQUOTE>
<BR>
P-15-18 Sakai, Jun 
<BLOCKQUOTE>An Association Study Between Atypical Psychoses and Dopamine
D2 Receptor Gene</BLOCKQUOTE>
<BR>
P-15-19 Imamura, Akira 
<BLOCKQUOTE>Anticipation and Triplet Repeats in Schizophrenia</BLOCKQUOTE>
<BR>
P-15-20 Nanko, Shinichiro 
<BLOCKQUOTE>Association of Neurotrophin-3 Gene Variant with Severe Forms
of Schizophrenia</BLOCKQUOTE>
<BR>
P-15-21 Silver, Henry 
<BLOCKQUOTE>Chronic Fluvoxamine Treatment Reduces Platelet Mao Activity
in Medicated Chronic Schizophrenics</BLOCKQUOTE>
<BR>
P-15-22 Igarashi, Yoshito 
<BLOCKQUOTE>Monoamine Metabolism in Acute Methamphetime Psychosis - Comparison
with Schizophrenia</BLOCKQUOTE>
<BR>
P-15-23 Regland, Bjorn T 
<BLOCKQUOTE>Disturbances of One-Carbon Metabolism in Schizophrenia</BLOCKQUOTE>
<BR>
P-15-24 Grunze, Heinz DR 
<BLOCKQUOTE>Impaired LTP of Recurrent Inhibition onto CA 1 Hippocampal Pyramidal
Cells as a Cellular Basis of Schizophrenia</BLOCKQUOTE>
<BR>
P-15-25 Woo, Won H 
<BLOCKQUOTE>Changes of Plasma Prolactin, ACTH, Cortisol and Clinical Symptoms
After ECT in Schizophrenia</BLOCKQUOTE>
<BR>
P-16-1 Burnett, Frances E 
<BLOCKQUOTE>Hydrocortisone Induced Corticotropin Responses During the Menstrual
Cycle</BLOCKQUOTE>
<BR>
P-16-2 Steiger, Axel 
<BLOCKQUOTE>Effects of Metyrapone Treatment Upon Hormonal Secretion and
Sleep</BLOCKQUOTE>
<BR>
P-16-3 Steiger, Axel 
<BLOCKQUOTE>Growth Hormone-Releasing Peptide Stimulates Growth Hormone,
ACTH and Cortisol Secretion and Sleep in Man</BLOCKQUOTE>
<BR>
P-16-4 Thakore, Jogin H 
<BLOCKQUOTE>Effect of Fluoxetine on Dex-Induced GH Release in Depression</BLOCKQUOTE>
<BR>
P-16-5 Terao, Takeshi 
<BLOCKQUOTE>Effect of Serum Cholesterol Levels On Neuroendocrine Responses
in Healthy Subjects</BLOCKQUOTE>
<BR>
P-16-6 Reist, Christopher 
<BLOCKQUOTE>The Paroxetine Challenge Test for In Vivo Evaluation of Serotonin
Function in Man</BLOCKQUOTE>
<BR>
P-16-7 Kubota, Masaharu 
<BLOCKQUOTE>Adrenergic Nervous Systems Affect the Clonidine Challenge Test</BLOCKQUOTE>
<BR>
P-16-8 Niwa, Masanobu 
<BLOCKQUOTE>Ipsapirone Modulates Clonidine Challenge Test in Rats</BLOCKQUOTE>
<BR>
P-16-9 Norman, Trevor R 
<BLOCKQUOTE>Neuroendocrine Responses to Ipsapirone in Patients With Panic
and Obsessive Compulsive Disorders</BLOCKQUOTE>
<BR>
P-16-10 Nathan, Pradeep J 
<BLOCKQUOTE>The Role of the Serotonergic System on Nocturnal Cortisol and
Prolactin Secretion in Healthy Humans</BLOCKQUOTE>
<BR>
P-17-1 Buchsbaum, Monte S 
<BLOCKQUOTE>Positron Emission Tomography in Schizophrenics Treated with
Sertindole and Haloperidol</BLOCKQUOTE>
<BR>
P-17-2 Williams, Stephen A 
<BLOCKQUOTE>Sustained 5HT2A Receptor Occupancy of Ziprasidone Using Pet
Ligand 18F Setoperone in Healthy Volunteers</BLOCKQUOTE>
<BR>
P-17-3 Chinchilla, Alfonso 
<BLOCKQUOTE>99Tc-HMPAO-Spect in Bulimia Nervosa: A Pre and Post Fluoxetine
Treatment Study</BLOCKQUOTE>
<BR>
P-17-4 Cebollada, Alberto 
<BLOCKQUOTE>Qualitative Analysis of Cerebral Images in Schizophrenia Patients:
A 99-Tc-HMPAO Spect Study</BLOCKQUOTE>
<BR>
P-17-5 Jalenques, Isabelle 
<BLOCKQUOTE>Regional Cerebral Perfusion by TC-99M HMPAO Spect Before Any
Treatment in Alzheimer's Disease</BLOCKQUOTE>
<BR>
P-17-6 Vega-Pinero, Miguel 
<BLOCKQUOTE>A Study of Regional Blood Flow with 99Tc-HMPAO Spect in Eating
Disorders</BLOCKQUOTE>
<BR>
P-17-7 Takahashi, Yoshito 
<BLOCKQUOTE>Dopamine and Serotonin Receptor Occupancy by Atypical Antipsychotic
Drugs in Vivo</BLOCKQUOTE>
<BR>
P-17-8 Mager, Torsten 
<BLOCKQUOTE>Optimized Analysis of the D2 Dopamine Receptor Occupancy By
Image Fusion of Corresponding I- 123 IBZM-Spect and MR-Data</BLOCKQUOTE>
<BR>
P-17-9 Coppola, Richard 
<BLOCKQUOTE>Neuroleptic Dose Related D2 Receptor Occupancy Measured By IBZM
Spect</BLOCKQUOTE>
<BR>
P-17-10 Dietrich, Bruno 
<BLOCKQUOTE>Pharmaco EEG Effects of S(+) DN-2327 Enantiomer and DN-2327
Racemate</BLOCKQUOTE>
<BR>
P-17-11 Ravindran, Arun V 
<BLOCKQUOTE>Quantitative Electroencephalography in Primary Dysthmia</BLOCKQUOTE>
<BR>
P-17-12 Tauscher, Johannes 
<BLOCKQUOTE>EEG Coherence Analysis Shows &quot;Hypofrontality&quot; in Schizophrenic
Patients</BLOCKQUOTE>
<BR>
P-17-13 Pannelli, Giorgio 
<BLOCKQUOTE>Acute CEEG Modifications After Clozapine and Haloperidol Administration
in Schizophrenia</BLOCKQUOTE>
<BR>
P-17-14 Pannelli, Giorgio 
<BLOCKQUOTE>EEG Mapping Longitudinal Evaluation of Patients Affected By
Schizophreniform Disorder</BLOCKQUOTE>
<BR>
P-17-15 Takashima, Atsuko 
<BLOCKQUOTE>Difference of Processing Among Parts-of-Speech using Event-Related
Potentials</BLOCKQUOTE>
<BR>
P-17-16 Yanai, Ichiro 
<BLOCKQUOTE>Auditory P300 in Depression with Silent Cerebral Infarction</BLOCKQUOTE>
<BR>
P-17-17 Ohta, Katsuya 
<BLOCKQUOTE>Contextual Effects and Repetition Effects on N400 and Late Positive
Component</BLOCKQUOTE>
<BR>
P-17-18 Ogura, Chikara 
<BLOCKQUOTE>Effects of Dopamine Related Drugs on Event-Related Potentials
and Its Relation to the Law of Initial Value</BLOCKQUOTE>
<BR>
P-17-19 Jarema, Marek 
<BLOCKQUOTE>Neuroleptic Treatment and MRI Brain Changes in Schizophrenia</BLOCKQUOTE>
<BR>
P-17-20 Takahashi, Sakae 
<BLOCKQUOTE>Discrimination Among Schizophrenic, Depressive and Normal Control
Groups using Neurophysiological Tests</BLOCKQUOTE>
<BR>
P-17-21 Blennow, Kaj 
<BLOCKQUOTE>Synaptic Loss in the Thalamus of Schizophrenics</BLOCKQUOTE>
<BR>
P-17-22 Sharma, Tonmoy 
<BLOCKQUOTE>Loss of Cerebral Asymmetry in Familial Schizophrenia A Volumetric
Study Using Unbiased Stereology</BLOCKQUOTE>
<BR>
P-18-1 Papadimitriou, George N 
<BLOCKQUOTE>Electroconvulsive Therapy in Elderly Depressed Patients</BLOCKQUOTE>
<BR>
P-18-2 Papadimitriou, George N 
<BLOCKQUOTE>Cognitive Effects of ECT after TRH Administration</BLOCKQUOTE>
<BR>
P-18-3 Berk, Michael 
<BLOCKQUOTE>Anaesthetic Induction for ECT with Etomidate is Associated with
Longer Seizure Duration than Thiopentone: A Controlled Randomised Trial</BLOCKQUOTE>
<BR>
P-18-4 Sirota, Pinkhas 
<BLOCKQUOTE>The Influence of ECT on Olfactory Memory</BLOCKQUOTE>
<BR>
P-18-5 Bersani, Giuseppe 
<BLOCKQUOTE>NGF Plasma Levels in Psychiatric Patients Treated With ECT:
Results at IV and VIII ECT</BLOCKQUOTE>
<BR>
P-18-6 Hatzimanolis, John 
<BLOCKQUOTE>Prolactin and Cortisol Release During ECT are not Influenced
by Pretreatment with the Serotonin Receptor Agonist Sumatriptan</BLOCKQUOTE>
<BR>
P-18-7 Yoshida, Keizo 
<BLOCKQUOTE>Neurotransmitter Releasing Response After Single and Repeated
Electroconvulsive Shock Treatment</BLOCKQUOTE>
<BR>
P-18-8 Nalepa, Irena 
<BLOCKQUOTE>Modulation By Nifedipine of ECS Action on Second Messenger and
Protein Kinase C-Related Effects</BLOCKQUOTE>
<BR>
P-18-9 Ishihara, Kumatoshi 
<BLOCKQUOTE>Repeated Electroconvulsive Shock-Induced Changes of Serotonin
Responses in Hippocampal CA1</BLOCKQUOTE>
<BR>
P-18-10 Dunner, David L 
<BLOCKQUOTE>The Effect of Substance Abuse on the Course of Bipolar Disorder</BLOCKQUOTE>
<BR>
P-18-11 Fujiwara, Yutaka 
<BLOCKQUOTE>Comparison Between Early-and Late-Onset Rapid Cycling Affective
Disorders</BLOCKQUOTE>
<BR>
P-18-12 Gillman, Peter K 
<BLOCKQUOTE>Lithium Appears to Inhibit Recovery From the Depressive Phase
of Bipolar Disorder</BLOCKQUOTE>
<BR>
P-18-13 Robertson, Brian A 
<BLOCKQUOTE>Fluoxetine-Induced, Rapid Cycling Mania in an Adolescent</BLOCKQUOTE>
<BR>
P-18-14 Fujikawa, Tokumi 
<BLOCKQUOTE>Relationship Between Late-Onset Mania and Silent Cerebral Infarction</BLOCKQUOTE>
<BR>
P-18-15 Mitchell, Philip B 
<BLOCKQUOTE>Linkage Analyses of Chromosomes 6, 16, 18 and 21 in Bipolar
Disorder Pedigrees</BLOCKQUOTE>
<BR>
P-18-16 Mitchell, Philip B 
<BLOCKQUOTE>Increased Levels of Gds in Platelets of Euthymic Bipolar Affective
Disorder Patients</BLOCKQUOTE>
<BR>
P-18-17 Fabian, James E 
<BLOCKQUOTE>Effects of the Calcium Antagonist Diltiazem on the Amphetamine
Model of Mania in Humans</BLOCKQUOTE>
<BR>
P-18-18 Grunze, Heinz DR 
<BLOCKQUOTE>Lamotrigine May Limit Pathological Excitation By Modulating
Sodium - and Potassium Currents</BLOCKQUOTE>
<BR>
P-18-19 Shinkai, Takahiro 
<BLOCKQUOTE>Effects of Lithium and Carbamazepine on Serum Calucium Concentrations
in Neuropsychiatric Patients</BLOCKQUOTE>
<BR>
P-18-20 Okamoto, Yasumasa 
<BLOCKQUOTE>Inhibitory Effects of Lithium Ion on Intracellular Calcium Movements</BLOCKQUOTE>
<BR>
P-18-21 Mork, Arne 
<BLOCKQUOTE>Lithium: cAMP Synthesis and Serotonin Release in the Brain of
Freely Moving Rats</BLOCKQUOTE>
<BR>
P-18-22 Zlenko, Helen T 
<BLOCKQUOTE>New Anticonvulsive Compounds of Sulfonamide Derivatives Line</BLOCKQUOTE>
<BR>
P-18-23 Sapronov, Nikolai S 
<BLOCKQUOTE>Convulsive and Anticonvulsive Influence of Some L-Asparagic
Acid Derivatives</BLOCKQUOTE>
<BR>
P-18-24 Nomaguchi, Mitsuo 
<BLOCKQUOTE>The Effects of Zonisamide and Other Antiepileptic Drugs When
Administered Incombination on the Seizure-Susceptible El Mouse</BLOCKQUOTE>
<BR>
P-19-1 van Harten, Jaap 
<BLOCKQUOTE>Flesinoxan Improves Cognition in the Healthy Elderly</BLOCKQUOTE>
<BR>
P-19-2 Danion, Jean-Marie J M 
<BLOCKQUOTE>Effects of Benzodiazepines on Conscious and Automatic Memory
Processes</BLOCKQUOTE>
<BR>
P-19-3 Sapronov, Nikolai S 
<BLOCKQUOTE>Impairment of Fine Short Term Memory Mechanisms With Some Neurotropic
Drugs</BLOCKQUOTE>
<BR>
P-19-4 Le Poncin, Monique 
<BLOCKQUOTE>Nutrient Presentation of Cognitive and Memory Performances</BLOCKQUOTE>
<BR>
P-19-5 Bugarski-Kirola, Dragana 
<BLOCKQUOTE>Transient Global Amnesia-Possible Aetiopathogenetic Mechanisms</BLOCKQUOTE>
<BR>
P-19-6 Wang, Jian Yi 
<BLOCKQUOTE>Ginkgo Biloba in the Treatment of Senile Dementia</BLOCKQUOTE>
<BR>
P-19-7 Nivataphand, Raviwan 
<BLOCKQUOTE>Treatment With &quot;Deproteinized Calves' Blood Extract&quot;
in Mild and Moderate Alzheimer's Disease</BLOCKQUOTE>
<BR>
P-19-8 Yamamoto, Megumi 
<BLOCKQUOTE>Adenylyl Cyclase Immunoreactivity in Dementia of the Alzheimer
Type</BLOCKQUOTE>
<BR>
P-19-9 Yamada, Misa 
<BLOCKQUOTE>The Study of Differentially Expressed Molecules in Alzheimer's
Disease Brain</BLOCKQUOTE>
<BR>
P-19-10 Gale, Tim M 
<BLOCKQUOTE>A Connectionist Model of Semantic Degradation in Alzheimer's
Disease</BLOCKQUOTE>
<BR>
P-19-11 Ishikawa, Hiroki 
<BLOCKQUOTE>Calcium Mobilizing Action of Amyloid beta-Protein in Human Platelets</BLOCKQUOTE>
<BR>
P-19-12 Burbaeva, Gulnur Sh 
<BLOCKQUOTE>The Level of Glutamine Synthetase in Alzheimer's Disease Brain</BLOCKQUOTE>
<BR>
P-19-13 Koldunov, Victor V 
<BLOCKQUOTE>The Influence of Testenate on the Brain Functional Condition
of Aging</BLOCKQUOTE>
<BR>
P-19-14 Topka, Elvira E 
<BLOCKQUOTE>Neurotropic Effect of Testenate and Tocopherol in Androgen Insufficiency</BLOCKQUOTE>
<BR>
P-19-15 Lee, Ki Hyeong 
<BLOCKQUOTE>Efficacy of Indeloxazine Hydrochloride, a Cerebral Activator,
in Cerebral Ischemic Parients</BLOCKQUOTE>
P-19-16 Nakai, Masami 
<BLOCKQUOTE>Pharmacological Profile of OPC-14523 (2): Effects on Learning
and Memory Impairment</BLOCKQUOTE>
<BR>
P-19-17 Ukai, Makoto 
<BLOCKQUOTE>Further Characterization of Effects of Dynorphin on Galanin-
Induced Amnesia</BLOCKQUOTE>
<BR>
P-19-18 Skarsfeldt, Torben 
<BLOCKQUOTE>Differential Effect of Novel and Reference Antipsychotics on
Place Navigation of Rats in Morris Water Maze</BLOCKQUOTE>
<BR>
P-19-19 Alvarez, Xose A 
<BLOCKQUOTE>Comparative Effects of S9977-2 vs Tacrine on Passive Avoidance
Learning</BLOCKQUOTE>
<BR>
P-19-20 Nowakowska, Elzbieta 
<BLOCKQUOTE>The Influence of Fluoxetine on Memory, Anxiolytic Activity and
Locomotor Function in Rats</BLOCKQUOTE>
<BR>
P-19-21 Tottori, Katsura 
<BLOCKQUOTE>Pharmacological Profile of OPC-14523 (1): A Novel Sigma and
5-HT1a Receptor Agonist</BLOCKQUOTE>
<BR>
P-19-22 Yamamoto, Tsuneyuki 
<BLOCKQUOTE>Functional Differences of the Cerebral Cortex in Short-Term
Memory and Attention in Rats</BLOCKQUOTE>
<BR>
P-19-23 Jalenques, Isabelle 
<BLOCKQUOTE>Distribution of Glial Fibrillary Acidic Protein in the Cochlear
Adult and Aged Rats</BLOCKQUOTE>
<BR>
P-19-24 Woo, Won H 
<BLOCKQUOTE>Changes of Calbindin &amp; Parvalbumin Immunoreactive Neurons
in the Brain of Aging Rats</BLOCKQUOTE>
<BR>
P-19-25 Woo, Won N 
<BLOCKQUOTE>Changes of Neuropeptide Immunoreactive Neurons in the Cerebral
Cortex of Aging Rats</BLOCKQUOTE>
<BR>
P-19-26 Hermans, Emmanuel R 
<BLOCKQUOTE>Apparent Lack of Regulation of Muscarinic Receptors on Rat Brain
Synaptosomes</BLOCKQUOTE>
<BR>
P-19-27 Hiramatsu, Masayuki 
<BLOCKQUOTE>Effect of Dynorphine A (1-13) On Decrease in Acetylcholine Release
Induced By Carbachol in Rats</BLOCKQUOTE>
<BR>
P-19-28 Kobayashi, Tetsuya 
<BLOCKQUOTE>Enhancement of Acetylcholine Release by SA4503, A Novel Q1 Agonist,
in Rat Brain</BLOCKQUOTE>
<BR>
P-19-29 Matsuno, Kiyoshi 
<BLOCKQUOTE>Ameliorating Effect of SA4503, a Novel Q1 Agonist, on Memory
Impairments in Rats</BLOCKQUOTE>
<BR>
P-19-30 Ripova, Daniela B 
<BLOCKQUOTE>Effect of Postmortem Interval on Phospholipid and Fatty Acid
Composition in the Rat Brain</BLOCKQUOTE>
<BR>
P-19-31 Sugaya, Kiminobu 
<BLOCKQUOTE>Effect of &quot;Kangenkaryu&quot; on Cerebral Blood Flow and
Gene Expression in Rat</BLOCKQUOTE>
<BR>
P-19-32 Lees, Gordon J 
<BLOCKQUOTE>Prevention of Zinc Neurotoxicity with a Zinc Chelator</BLOCKQUOTE>
<BR>
P-19-33 Schettini, Gennaro 
<BLOCKQUOTE>Beta 25-35 Induces Neurotoxicity by Altering Calcium Homeostasis
in Cerebellar Granule Cells</BLOCKQUOTE>
<BR>
P-19-34 Conway, Elizabeth L 
<BLOCKQUOTE>Spermine Neurotoxicity in the Hippocampus: A Behavioural and
Neurochemical Study</BLOCKQUOTE>
<BR>
P-19-35 Fernandez-Novoa, Lucia 
<BLOCKQUOTE>Effects of Anapsos on the Activity of Sod in an Animal Model
of Neurodegeneration</BLOCKQUOTE>
<BR>
P-19-36 Fernandez-Novoa, Lucia 
<BLOCKQUOTE>Effects of Anapsos on Brain Histamine and IL-1B Levels in an
Animal Model of Neurodegeneration</BLOCKQUOTE>
<BR>
P-19-37 Alvarez, Xose A 
<BLOCKQUOTE>Effects of Anapsos on Longevity, Behaviour and Brain Neurochemistry
in Mice</BLOCKQUOTE>
<BR>
P-19-38 Fukui, Kenji 
<BLOCKQUOTE>Electron Microscopical Study on Rat Dentate Gyrus Following
Chronic Toluene Exposure</BLOCKQUOTE>
<BR>
P-19-39 Alvarez, Xose A 
<BLOCKQUOTE>Brain Neurotoxic Lesions in Rats: Study of the Neuroprotective
Effects jof CDP-Choline</BLOCKQUOTE>
<BR>
P-19-40 Ishimaru, Hirohisa 
<BLOCKQUOTE>Cystatin C and Apolipoprotein E Immunoreactivity in CA1 Neurons
in Ixchemic Gerbil Hippocampus</BLOCKQUOTE>
<BR>
P-19-41 Gundlach, Andrew L 
<BLOCKQUOTE>MAO-B Enzyme and I2-Imidazoline Receptor Binding Sites After
Excitotoxic Lesions of Rat Hippocampus</BLOCKQUOTE>
<BR>
P-19-42 George, Bobby 
<BLOCKQUOTE>Studies on Lithium-Pilocarpine Neurotoxicity in Rats</BLOCKQUOTE>
<BR>
P-19-43 Sethy, Vimala H 
<BLOCKQUOTE>Neuroprotective Effects of the Pyrrolopyrimidine U-104067F Against
3-Acetylpyridine Neurotoxicity</BLOCKQUOTE>
<BR>
P-19-44 Shen, Pei-Juan 
<BLOCKQUOTE>Effect of Adrenoceptor Blockade on Cortical c-fos mRNA After
Minimal Cortical Lesion</BLOCKQUOTE>
<BR>
P-19-45 Draganic, Pero 
<BLOCKQUOTE>Calcium Channel Blocker Felodipine and Motor Activity of Spinal
Cord Injured Rabbits</BLOCKQUOTE>
<BR>
P-20-1 Tang, Siu W 
<BLOCKQUOTE>Cytochrome P450 Inhibition: Interactions With Calcium and Serotonin
Transporter</BLOCKQUOTE>
<BR>
P-20-2 Araki, Hiroaki 
<BLOCKQUOTE>Do PG12 Derivatives Block the Extraordinary Increase of Neuronal
Ca2+ Levels?</BLOCKQUOTE>
<BR>
P-20-3 Katay, Livia 
<BLOCKQUOTE>Effect of Vasapressine on C1-Uptake in Cultured Astroglia</BLOCKQUOTE>
<BR>
P-20-4 Yoshimura, Reiji 
<BLOCKQUOTE>Effects of a Long-term Treatment With Carbamazepine On Catecholamine
Secretion in Adrenal Medullary Cells</BLOCKQUOTE>
<BR>
P-20-5 Gundlach, Andrew L 
<BLOCKQUOTE>Effects of Imidazoline Drugs on Early Response Gene Activity
in Brain, Kidney and Adrenal Gland</BLOCKQUOTE>
<BR>
P-20-6 Camacho-Ochoa, Marlene 
<BLOCKQUOTE>[3H]-Pramipexole Receptor Binding Studies Reveal D3 Receptors
in Basal Ganglia/Mesolimbic Areas</BLOCKQUOTE>
<BR>
P-20-7 Hatta, Shinichi 
<BLOCKQUOTE>Participation of Vitamin B12 in the Regulation of Neuronal Adenylyl
Cyclase Signal Transduction</BLOCKQUOTE>
<BR>
P-20-8 Hermans, Emmanuel R 
<BLOCKQUOTE>Role of G-Protein in the Control of Neurotensin Receptor Internalization</BLOCKQUOTE>
<BR>
P-20-9 Jalenques, Isabelle 
<BLOCKQUOTE>Immunohistochemical Localization of Neurotrophin Receptors in
the Adult Rat Ventral Cochlear Nucleaus</BLOCKQUOTE>
<BR>
P-20-10 Jalenques, Isabelle 
<BLOCKQUOTE>Distribution of TrK Receptors in the Adult Dorsal Cochlear Nucleus
of the Rat</BLOCKQUOTE>
<BR>
P-20-11 Marazziti, Donatella 
<BLOCKQUOTE>Effects of Divalent Cations and Nucleotides on the Binding of
[3H]8-PH-DPAT in Human Brain</BLOCKQUOTE>
<BR>
P-20-12 Yamada, Mitsuhiko 
<BLOCKQUOTE>The Binding of Some Psychotropic Drugs at the Molecularly Cloned
Human Histamine H1 Receptor Expressed by CHO Cells</BLOCKQUOTE>
<BR>
P-20-13 Sapronov, Nikolai S 
<BLOCKQUOTE>Receptors of Chromatin for Drug Discovery</BLOCKQUOTE>
<BR>
P-20-14 Quock, Raymond M 
<BLOCKQUOTE>Involvement of the GABAa Receptor Gamma3 Subunit in a Behavioural
Effect of Nitrous Oxide (N20)</BLOCKQUOTE>
<BR>
P-20-15 Toyoda, Hirotaka 
<BLOCKQUOTE>The Effect of Sulpiride on NMDA Receptor mRNA Levels in Rat
Whole Brain</BLOCKQUOTE>
<BR>
P-20-16 Blume, Gail L 
<BLOCKQUOTE>Autoradiography of NA+-Dependent L-Glutamate Transport in the
Rat Brain</BLOCKQUOTE>
<BR>
P-21-1 Park, Doo B 
<BLOCKQUOTE>Changes of the Lymphocyte Subset in Major Depressive Disorder
and Schizophrenia</BLOCKQUOTE>
<BR>
P-21-2 Park, Doo B 
<BLOCKQUOTE>A Study of the Relationship Between Circulating - NK - Cell
and Personality Characteristics in Neurotic Patients</BLOCKQUOTE>
<BR>
P-21-3 Sulcova, Alexandra E 
<BLOCKQUOTE>Concurrent Treatment with Verapamil Decreases Immune Response
to Cannabimimetic Anandamide</BLOCKQUOTE>
<BR>
P-22-1 Hummer, Martina 
<BLOCKQUOTE>Patients Selection in Clinical Trials with Antipsychotics</BLOCKQUOTE>
<BR>
P-22-2 Ortega-Soto, Hector A 
<BLOCKQUOTE>Typical Antipsychotics: The Threshold Strategy</BLOCKQUOTE>
<BR>
P-22-3 Lambert, Tim 
<BLOCKQUOTE>Interrater Reliability and the PANSS - What Does It Tell Us
About Efficacy in Neuroleptic Trials?</BLOCKQUOTE>
<BR>
P-22-4 Gallhofer, Bernd 
<BLOCKQUOTE>Effects of Conventional and Atypical Antipsychotic Agents on
Cognitive Function in Schizophrenia</BLOCKQUOTE>
<BR>
P-22-5 Addington, Jean M 
<BLOCKQUOTE>Cognitive Functioning in Schizophrenia: A Trial of Risperidone
Versus Haloperidol</BLOCKQUOTE>
<BR>
P-22-6 Ciprian-Ollivier, Jorge 
<BLOCKQUOTE>Twenty Years of Clinical Experience with the Use of Clozapine
in Severe Psychotic Patients</BLOCKQUOTE>
<BR>
P-22-7 Bender, Stefan A 
<BLOCKQUOTE>Treatment of Schizophrenia and Schizoaffective Disorder with
a Combination of Clozapine and Lithium</BLOCKQUOTE>
<BR>
P-22-8 Harrigan, Edmund P 
<BLOCKQUOTE>The Efficacy and Safety of 28-Day Treatment with Ziprasidone
in Schizophrenia/Schizoaffective Disorder</BLOCKQUOTE>
<BR>
P-22-9 Reeves, Karen 
<BLOCKQUOTE>The Efficacy and Safety of Two Fixed Doses of Ziprasidone in
Schizophrenia</BLOCKQUOTE>
<BR>
P-22-10 Ogura, Chikara 
<BLOCKQUOTE>Prediction of Clinical Efficacy of Antipsychotic Bromperidol,
Nemoapride, Mosapramine Using Multivariate Analysis of Variance</BLOCKQUOTE>
<BR>
P-22-11 Jeste, Dilip V 
<BLOCKQUOTE>Large, Multicentre, Open Trial of Risperidone in Schizophrenia</BLOCKQUOTE>
<BR>
P-22-12 Marazziti, Donatella 
<BLOCKQUOTE>Effectiveness of Glutamate Agonist on Negative Symptoms of Schizophrenia</BLOCKQUOTE>
<BR>
P-22-13 Murasaki, Mitsukuni 
<BLOCKQUOTE>Long Term-Treatment of a New Atypical Neuroleptic, SM-9018 on
Patients with Schizophrenia</BLOCKQUOTE>
<BR>
P-22-14 King, David J 
<BLOCKQUOTE>Seroquel (ICI 204636) - An Atypical Antipsychotic - Results
from Phase 3</BLOCKQUOTE>
<BR>
P-22-15 Jasovic-Gasic, Miroslava M 
<BLOCKQUOTE>Antidepressants in the Treatment of Depressive Syndrome in Schizophrenia</BLOCKQUOTE>
<BR>
P-22-16 Thakore, Jogin H 
<BLOCKQUOTE>Adjuvant Sertraline Treatment for Chronic Schizophrenia</BLOCKQUOTE>
<BR>
P-22-17 Alciati, Alessandra 
<BLOCKQUOTE>Neuroleptic Treatment of Psychotic Symptoms in HIV Seropositive
Patients</BLOCKQUOTE>
<BR>
<HR>
<P><CENTER><A HREF="index.htm#anchor689408"><IMG SRC="files.gif/smanlog.gif"
WIDTH="62" HEIGHT="57" ALIGN="BOTTOM" NATURALSIZEFLAG="3"></A></CENTER>
</BODY>
</HTML>
</DOC>